Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risperidone - ValiSeek

Next Previous
Search
Drug Profile

Risperidone - ValiSeek

Alternative Names: VAL-401

Latest Information Update: 18 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tangent Reprofiling
  • Developer Valiseek
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 18 Jun 2024 Discontinued - Phase-II for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Georgia (PO) (ValiRx website, June 2024)
  • 15 Feb 2022 ValiSeek has patent protection for VAL 401 in China, Europe, Israel, Japan, Mexico, New Zealand and USA before February 2022 (ValiSeek's pipeline, February 2022)
  • 15 Feb 2022 ValiSeek receives patent allowance for VAL 401 in China, Europe, Israel, Japan, Mexico, New Zealand and USA before February 2022 (ValiSeek's pipeline, February 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top